High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2021 Oct 28

PMID 34707388

Citations 4

Authors

Sisi Chang

Yahui Zhu

Yutan Xi

Fuyan Gao

Juanjuan Lu

Liang Dong

Chunzheng Ma

Honglin Li

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the role of DSCC1 in LUAD.

Patients And Methods: Based on TCGA and GTEx, the Wilcoxon rank-sum test was used to compare the expression differences of DSCC1 between the normal samples of GTEx combined TCGA and the unpaired tumor samples of TCGA, and to compare DSCC1 expression values between tumor tissues and paired normal LUAD tissues in the TCGA cohort. Kruskal-Wallis rank-sum test, Wilcoxon rank-sum test, and logistics regression were used to compare the relationship between the expression of DSCC1 and the clinicopathological parameters. The biological function of DSCC1 was annotated by GSEA and ssGSEA, while Kaplan-Meier and Cox regression analysis were used to evaluate the prognostic value of DSCC1. Furthermore, the time-dependent ROC curve was used to analyze the diagnostic efficacy of DSCC1 in LUAD.

Results: We downloaded the RNA-Seq data of 513 LUAD cases. The expression of DSCC1 was significantly correlated with T stage (OR = 1.04(1.02-1.07), P = 0.002), pathological stage (OR=1.03 (1.01-1.05), P = 0.008) and TP53 status (OR=1.10 (1.07-1.14), P < 0.001). The high expression of DSCC1 was significantly correlated with DSS (HR=1.56 (1.07-2.26), P = 0.021) and OS (HR=1.53 (1.14-2.05), P = 0.004). Moreover, ROC curve analysis (AUC=0.845, CI (0.820-0.870)) indicated DSCC1 as a potential diagnostic molecule for LUAD. In the group with high DSCC1 expression phenotype, down-regulation of EGFR signal, reduction of IL-6 deprivation, cell cycle, and p53 signal pathway were significantly abundant. Spearman correlation analysis showed that the expression of DSCC1 was positively correlated with the infiltration of Th2 cells, T Helper cells.

Conclusion: Our results suggest that DSCC1 may be an important biomarker for the treatment of LUAD.

Citing Articles

DSCC1 Identified as Promising Tumor Biomarker and Potential Therapeutic Target Through Comprehensive Multi-omics Analysis and Experimental Validation.

Cheng W, Lin P Mol Biotechnol. 2025; .

PMID: 39992486 DOI: 10.1007/s12033-025-01404-w.

Prognostic Significance of DSCC1, a Biomarker Associated with Aggressive Features of Breast Cancer.

Aljohani A Medicina (Kaunas). 2025; 60(12.

PMID: 39768811 PMC: 11677291. DOI: 10.3390/medicina60121929.

Transcription Factor E2F4 Promote Proliferation, Migration, and Invasion of Gastric Cancer Cells by transcriptionally activating DSCC1.

Baral S, Yu Y, Sun Q, Jiang M, Li R, Cheng Y Int J Biol Sci. 2024; 20(12):4978-4998.

PMID: 39309429 PMC: 11414385. DOI: 10.7150/ijbs.99590.

Decoding the DSCC1 gene as a pan-cancer biomarker in human cancers via comprehensive multi-omics analyses.

Wang J, Gilani S, Noor N, Ahmed M, Munazir M, Zubair A Am J Transl Res. 2024; 16(3):738-754.

PMID: 38586115 PMC: 10994803. DOI: 10.62347/YORR3755.

Complementary biomarkers of computed tomography for diagnostic grading of gastric cancer: DSCC1 and GINS1.

Zhu Y, Hou S, Kang C Aging (Albany NY). 2024; 16(5):4149-4168.

PMID: 38301047 PMC: 10968684. DOI: 10.18632/aging.205491.

References

Waga S, Stillman B . The DNA replication fork in eukaryotic cells. Annu Rev Biochem. 1998; 67:721-51. DOI: 10.1146/annurev.biochem.67.1.721. View

Mayer M, Gygi S, Aebersold R, Hieter P . Identification of RFC(Ctf18p, Ctf8p, Dcc1p): an alternative RFC complex required for sister chromatid cohesion in S. cerevisiae. Mol Cell. 2001; 7(5):959-70. DOI: 10.1016/s1097-2765(01)00254-4. View

Zhang J, Zhou X, Huang D, Luan C, Gu H, Ju M . Development of an Immune-Related Gene Signature for Prognosis in Melanoma. Front Oncol. 2021; 10:602555. PMC: 7874014. DOI: 10.3389/fonc.2020.602555. View

Kim J, MacNeill S . Genome stability: a new member of the RFC family. Curr Biol. 2003; 13(22):R873-5. DOI: 10.1016/j.cub.2003.10.048. View

Slotman G, Burchard K, Yellin S, Williams J . Prostaglandin and complement interaction in clinical acute respiratory failure. Arch Surg. 1986; 121(3):271-4. DOI: 10.1001/archsurg.1986.01400030025002. View

Caetano M, Hassane M, Van H, Bugarin E, Cumpian A, McDowell C . Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nat Commun. 2018; 9(1):4589. PMC: 6214980. DOI: 10.1038/s41467-018-07042-y. View

Gazy I, Kupiec M . The importance of being modified: PCNA modification and DNA damage response. Cell Cycle. 2012; 11(14):2620-3. DOI: 10.4161/cc.20626. View

Barrera L, Montes-Servin E, Barrera A, Ramirez-Tirado L, Salinas-Parra F, Banales-Mendez J . Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann Oncol. 2014; 26(2):428-35. DOI: 10.1093/annonc/mdu549. View

Batra R, Harder N, Gogolin S, Diessl N, Soons Z, Jager-Schmidt C . Time-lapse imaging of neuroblastoma cells to determine cell fate upon gene knockdown. PLoS One. 2012; 7(12):e50988. PMC: 3521006. DOI: 10.1371/journal.pone.0050988. View

10.

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

11.

Xu S, Liu R, Da Y . Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma. Thorac Cancer. 2018; 9(8):974-988. PMC: 6068465. DOI: 10.1111/1759-7714.12773. View

12.

Sher T, Dy G, Adjei A . Small cell lung cancer. Mayo Clin Proc. 2008; 83(3):355-67. DOI: 10.4065/83.3.355. View

13.

Ohta S, Shiomi Y, Sugimoto K, Obuse C, Tsurimoto T . A proteomics approach to identify proliferating cell nuclear antigen (PCNA)-binding proteins in human cell lysates. Identification of the human CHL12/RFCs2-5 complex as a novel PCNA-binding protein. J Biol Chem. 2002; 277(43):40362-7. DOI: 10.1074/jbc.M206194200. View

14.

Wu P, Zheng Y, Wang Y, Wang Y, Liang N . Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma. J Transl Med. 2020; 18(1):380. PMC: 7542703. DOI: 10.1186/s12967-020-02545-z. View

15.

Camidge D, Doebele R, Kerr K . Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019; 16(6):341-355. DOI: 10.1038/s41571-019-0173-9. View

16.

Ostrem J, Shokat K . Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016; 15(11):771-785. DOI: 10.1038/nrd.2016.139. View

17.

Waniczek D, Lorenc Z, Snietura M, Wesecki M, Kopec A, Muc-Wierzgon M . Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer. Arch Immunol Ther Exp (Warsz). 2017; 65(5):445-454. PMC: 5602054. DOI: 10.1007/s00005-017-0463-9. View

18.

Bremnes R, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S . The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol. 2010; 6(4):824-33. DOI: 10.1097/JTO.0b013e3182037b76. View

19.

Podust V, Podust L, GOUBIN F, Ducommun B, Hubscher U . Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the cyclin-dependent kinase inhibitor p21. Biochemistry. 1995; 34(27):8869-75. DOI: 10.1021/bi00027a039. View

20.

Huang R, Liao X, Li Q . Identification and validation of potential prognostic gene biomarkers for predicting survival in patients with acute myeloid leukemia. Onco Targets Ther. 2017; 10:5243-5254. PMC: 5679677. DOI: 10.2147/OTT.S147717. View